semaglutide approval date FDA Approves Oral as First GLP-1 Pill for Weight Loss FDA approves Ozempic® (semaglutide) as

GLP-1 receptor agonists like semaglutide slow gastric emptying and reduce appetite signaling

There are currently no FDA-approved GLP-1 receptor agonists that can be administered orally

These aren't trick questions or gotchas

Establish a regular bathroom routine , preferably 20-30 minutes after mealswhen the digestive system is the most active

Why Ozempic Can Cause Dizziness and Light-Headedness Understanding the mechanisms behind light-headedness helps patients and clinicians identify contributing factors and implement appropriate management strategies

Gastrointestinal effects are the most frequently reported and include: Nausea (particularly during dose escalation) Vomiting Diarrhoea and constipation Abdominal discomfort These effects are generally transient but can be distressing and may affect nutritional intake